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 Abstract 
Micro and macrovascular complications are the leading cause of morbidity and mortality in 
diabetic patients.  During the last decades attention has been focused on their early diagnosis 
and prevention. Diabetes related metabolic abnormalities:  insulin resistance, hyperglycaemia 
and dyslipidaemia along with oxidative stress and low- grade inflammation contribute to the 
development of endothelial dysfunction and macrovascular complications. Recent 
investigations indicate a potential role of adipocitokines originating from visceral adipose 
tissue: adiponectin, leptin, resistin and dipepetidyl peptidase- 4  (DPP-4) activity in the 
development of microvascular complications in diabetes. The association of these 
adipocitokines with the activity of endothelial synthetase (eNOS) involved into the 
metabolism of nitric oxide (NO) was documented in animal and cell culture studies. We 
hypothesize that lower adiponectin and higher leptin and resistin plasma concentration and 
DPP-4 activity are associated with the development and progression of diabetic microvascular 
complications by endothelial function impairment. 
A possible identification of new markers of the complex pathophysiologydevelopment and 
progression of microvascular complications in diabeteswill contribute to improved diagnosis 
followed by an individualized patients approach. 
 
 
 
 
Background 
The estimated prevalence of diabetes mellitus (DM) is currently about 382 million, or 8.3% of 
the world population aged 20-79 years (1). Due to the high impact on morbidity and mortality 
the prevention and early diagnosis of diabetic vascular complications is in the focus of 
scientific and professional interest. Diabetic retinopathy is the leading cause of blindness (2), 
diabetic nephropathy is the most important cause of renal failure (3), and macrovascular 
complications are the leading cause of death in more than two-thirds of diabetic patients (4). 
Endothelial cell dysfunction (ECD) is pathophysiologically related to all vascular 
complications of diabetes (5). Reduced bioavailability of nitric oxide (NO) (6) indirectly 
contributes to metabolic disorders of diabetes: hyperglycaemia and dyslipidaemia along with 
oxidative stress and low grade inflammation in the microvascular complications development 
(7).  
Visceral adipose tissue represents a hormonally active organ by secreting various 
adipocytokines implicated in the regulation of metabolic homeostasis (8). Studies 
demonstrating the effects of insulin resistance (IR) related adipocytokines: adiponectin, leptin, 
resistin and dipeptidyl peptidase-4 (DPP4) on endothelial NO sintetase (eNOS) have 
implicated their possible contribution to the development and progression of microvascular 
complications independently of traditional risk factors. However, their association with 
retinopathy, nephropathy and neuropathy through modulation of endothelial physiology has 
not been extensively studied. 
The hypothesis 
We hypothesisethat lower plasma concentrationof adiponectin, while higher concentrationof 
leptin, resistinandserum DPP4activity contribute to the development and progression of 
diabetic microvascular complications through endothelial function impairment.Insulin 
resistance (IR) contributes directly to the development of ECD modulating the activity of 
eNOS (9) and impairing other metabolic processes in diabetes (10). Prospective clinical 
studies have shown that abnormalities associated with ECD were causally related with the 
development and progression of microvascular complications in DM (11-13). Stehouwer et al. 
(2012) in longitudinal study in 328 patients with type 2 diabetes (T2DM) has shown that the 
level of ECD was associated with progression of nephropathy both in relation to and 
independently of traditional risk factors (14). The results of cross-sectional studies in patients 
with type 1 diabetes (T1DM) have also indicated that ECD might be more strongly associated 
with the development of microvascular complications in comparison with traditional risk 
factors (15). For that reason it seems to be of special scientific and clinical interest to 
investigate for new ECD related risk factors associated with the development and progression 
of microvascular complications in diabetes. 
Evaluation of the hypothesis 
Leptin is the oldest known adipocytokine (16). A higher plasma concentration of leptin is 
associated with the development and progression of microvascular complications in patients 
with T2DM (17-19). At the molecular level the effectof leptinonendothelial functionis unclear 
as leptin both stimulates the activity ofeNOS andreducesthe bioavailability ofL-
argininerequiredfor NO synthesis(20-22). In addition, the results of studies exploring the 
relationship between leptin and microvascularcomplications in patients with T1DM 
arecontroversial(23). 
Adiponectin is the most extensively studied adipocytokine in the context of their association 
with microvascular complications in diabetes. In T2DM plasma concentration is inversely 
associated with retinopathy (25) and urinary albumin excretion rate (UAE), an early marker of 
renal microvasculature (26). However, in T1DM the relationof adiponectinwithretinopathy, 
albuminuriaandnephropathyis not fully understood(20,29-31). Insome studies a positive 
correlationof adiponectinwithretinopathy andalbuminuria in T1DM was found (29, 30). In 
animal and cell culture studies adiponectin increased the bioavailability of NO directly, 
stimulating eNOS, and indirectly, by reducing the concentration of superoxide products (27-
29). Sharma et al. (2008) have shown in an animal model of T1DM that the retraction of 
podocyte cells representing the primary changes in diabetic nephropathy correlated with the 
superoxide concentrations (32). To explain elevatedconcentrationsof adiponectininpatients 
with T1DM andmicrovascular complications the authorhypothesizedthat an increase 
inadiponectin level might represent aprotective mechanism aimed to suppress superoxide 
effects on eNOS(31, 33). 
An elevated plasma concentration of resistin was also found in T1DM and T2DM. Its effect 
on IR is thought to be mediated through proinflammatory activity (34). The association of 
resistin with the prevalence of microvascular complications has not been extensively 
investigated. Azab et al. (2012) (35) have recently demonstrated in 30 patients with T2DM 
that resistin concentrations was associated with retinopathy. This is in support to the results of 
Osawa et al. (2007) who previously showed resistin relations with all microvascular 
complications in T2DM (37). However, other studies have not confirmed their results (36). It 
was not clarified whether resistin effect on inhibition of eNOS activity (37) and the 
development and progression of microvascular complications is independent of low-grade 
inflammation and IR (38).  
The results of recent experimental studies suggest an increased expression of DPP-4 in 
adipocytes of visceral fat and increased serum enzymes in patients with IR and T2DM (39, 
40). In vitro studies also suggest a possible link between DPP4 activity and renovascular 
protective effect (41, 42). However, the role of the serum DPP-4 enzyme in the pathogenesis 
of chronic microvascular complications in diabetes has not been systematically investigated. 
Inhibition of DPP4 activity leads to increased eNOS activity, although it is not clear whether 
this represent a directeffect ofDPP4 activity (43-45). 
Conclusion 
We hypothesisethat lower plasma concentrationof adiponectin, while higher concentrationof 
leptin, resistinandserum DPP4activity contribute to the development and progression of 
diabetic microvascular complications mediatingendothelial function impairment. Our 
assumptionrepresents the first interdisciplinaryapproach in order to clarify thecomplex 
pathogenesisof microvascularcomplicationsindiabetes.This novel approach aims to acquire 
the developmentof an individualized approachto diagnosis, prevention and treatment of 
diabetes related vascular complications. 
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